Accenture has invested in BehaVR, which is a leading innovator in virtual reality (VR) digital therapeutics and digital wellness experiences.
Recently, BehaVR merged with OxfordVR, which is a leader in science-based VR treatments for severe mental illnesses and a spin-out of Oxford University.
The newly combined entity will provide comprehensive, VR-based cross-acuity therapeutic interventions for mental health. The part of a digital therapeutics market is expected to exceed $13B by 2027, according to Accenture.
Through its proprietary delivery platform for creating, operating, and validating digital therapeutics solutions, the BehaVR platform facilitates personalized experiences that are adapted in real-time based on biometrics, protocols, and machine learning models.
Healthcare leaders expect virtual reality and the metaverse to positively impact the future of care, according to the Accenture Digital Health Technology Vision 2022 report, which explains how more meaningful, tailored experiences can further humanize healthcare.
BehaVR is now part of Accenture Ventures’ Project Spotlight, an engagement and investment program that connects emerging technology startups with the Global 2000 to fill strategic innovation gaps.